Home > Press > Leading Organizations Support Lux Executive Summit
Leading Organizations Support First Annual Lux Executive Summit
New York, NY | September 22, 2005
Lux Research, the world’s leading research and advisory firm for nanotechnology, today announced that it has received overwhelming support from the foremost organizations involved in nanotech, who have signed on as major sponsors of the inaugural Lux Executive Summit (www.luxexecutivesummit.com). The event will be held at the Charles Hotel in Cambridge, MA on October 24–25, 2005.
Premier Partners Deloitte and Foley & Lardner are joined by Select Partner 3i, Presenting Partners Biophan Technologies, Evident Technologies, NanoDynamics, NaturalNano, Nucryst Pharmaceuticals and pSivida, and Visibility Partner Gradient Corporation. Media and Association Partners include Technology Review, Forbes/Wolfe Nanotech Report, NanoBusiness Alliance, Capital IQ, Massachusetts Nanotech Exchange, Computing in Science and Engineering, IBF’s Nanotech Investing Forum, Nanotechnology Law & Business, The Executive Forum, PR Newswire, Strategic News Service, and TinyTechJobs.
“We’re excited to welcome these pioneering companies and organizations to the Lux Executive Summit,” said Peter Hebert, CEO of Lux Research. “Their participation is a testament to the unique value of our content and program as well as the high caliber of Lux Executive Summit attendees.”
"As a leading provider of legal services for nanotech companies, Foley & Lardner is pleased to be a part of this event, which features many of the thought leaders in nanotech today," said Steve Maebius, Leader of Foley's Nanotechnology Industry Team.
“Evident Technologies continues to grow and introduce next-generation products based on our proprietary quantum dot technology and it’s important to communicate with the industry’s decision-makers and influencers,” said Clinton Ballinger, CEO of Evident Technologies. “The Lux Executive Summit is a perfect forum to network with nanotech leaders and we’re looking forward to participating in the event.”
“As one of the world’s most promising nanobiotech companies, pSivida is poised to bring new and innovative products to the healthcare market," said Gavin Rezos, Managing Director of pSivida Limited. "Raising the profile of our business to the important U.S. healthcare and investment community is critical to our business. The Lux Executive Summit provides, in one forum, an opportunity to mix with some of the most experienced and key executives in the nano world and we are very pleased to be a participant."
For additional event details and early registration, please visit www.luxexecutivesummit.com/
About Lux Research:
Lux Research is the world's leading nanotechnology research and advisory firm. We help our clients make better decisions to profit from nanoscale science and technology, tapping into our analysts' unique expertise and unrivaled network. Our clients include top decision makers at large corporations, portfolio managers and analysts at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers.
For Lux Executive Summit registration and additional event details, please visit www.luxexecutivesummit.com
For more information, please visit www.luxresearchinc.com
Copyright © Lux Research
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Special UO microscope captures defects in nanotubes: University of Oregon chemists provide a detailed view of traps that disrupt energy flow, possibly pointing toward improved charge-carrying devices October 21st, 2014
Super stable garnet ceramics may be ideal for high-energy lithium batteries October 21st, 2014
Could I squeeze by you? Ames Laboratory scientists model molecular movement within narrow channels of mesoporous nanoparticles October 21st, 2014
Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014